OGN (OriginToken) fluctuated 80.3% in 24 hours: Driven by protocol buybacks and on-chain whale activity resonance
Bitget Pulse2026/03/12 00:58Volatility Brief
OGN experienced significant price volatility in the past 24 hours, surging from a low of $0.0188 to a high of $0.0339. The current price is $0.0273, with an amplitude fluctuation reaching 80.3%. Trading volume skyrocketed to about $25.1–26.28 million, a more than 1200% increase compared to the previous period, with clear signs of net capital inflow and markedly higher market activity.
Brief Analysis of the Cause of Abnormal Movement
- Continuous Protocol Token Buyback: Origin Protocol DAO is buying back OGN using protocol revenue. Over 7 million tokens were bought back in the first week of this month, with a cumulative total exceeding 75 million (accounting for 11.4% of circulating supply), and will continue to do so until Q2 2026, supporting a price rebound.
- On-chain Whale Accumulation and Large Transactions: On-chain data shows active whale behavior, with major holders switching from selling to accumulating, driving a breakout from the downtrend channel. Trading volume and whale participation increased synchronously.
The main factors are the buyback mechanism and whales working together. There has been no new official announcement, but the results of the mechanism have manifested within 24 hours.
Market Views and Outlook
Market sentiment is bullish overall, with the community and analysts viewing the buyback and channel breakout as catalysts. Target price levels are set at $0.1057–0.17, with the staking ratio maintaining a high level of 49.3%. Risk warnings include short-term retracement pressure and linkage with the broader market, so attention should be paid to continued buyback execution and on-chain sustainability.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
